Cargando…

Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study

Background: Anti-drug antibodies to infliximab (ATI) and adalimumab (ATA) are associated with loss of response to tumor necrosis factor antagonist (anti-TNF) therapy in inflammatory bowel disease (IBD). We evaluated the relationship between patient sex and serum TNF antagonist drug and antibody conc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shehab, Mohammad, Alasfour, Hajer, Abdullah, Israa, Alhendi, Ghadeer, Alhadab, Anwar, Alfadhli, Ahmad, Ziyab, Ali H., Battat, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733246/ https://www.ncbi.nlm.nih.gov/pubmed/35004778 http://dx.doi.org/10.3389/fmed.2021.801532

Ejemplares similares

Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease
por: Abdullah, Israa, et al.
Publicado: (2021)

Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study)
por: Alrashed, Fatema, et al.
Publicado: (2023)

Impact of tumor necrosis factor antagonist combination and anti-integrin therapies on body mass index in inflammatory bowel disease: A cross-sectional study
por: Shehab, Mohammad, et al.
Publicado: (2023)

Impact of biologics and small molecules for inflammatory bowel disease on COVID‐19‐related hospitalization and mortality: A systematic review and meta‐analysis
por: Alrashed, Fatema, et al.
Publicado: (2022)

Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis
por: Alrashed, Fatema, et al.
Publicado: (2021)

Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-Term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective Study
por: Shehab, Mohammad, et al.
Publicado: (2022)

COVID-19 Vaccine Booster Dose Willingness among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study
por: Shehab, Mohammad, et al.
Publicado: (2022)

Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease
por: Abdullah, Israa, et al.
Publicado: (2022)

Comparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritis
por: Martínez-Santana, Virginia, et al.
Publicado: (2013)

COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional Study
por: Shehab, Mohammad, et al.
Publicado: (2021)

Medication-Related Burden and Medication Adherence Among Geriatric Patients in Kuwait: A Cross-Sectional Study
por: Awad, Abdelmoneim, et al.
Publicado: (2020)

Beliefs of parents in Kuwait about thirdhand smoke and its relation to home smoking rules: A cross-sectional study
por: Shehab, Kawthar, et al.
Publicado: (2021)

The Combination of Antagonistic Drugs
Publicado: (1897)

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020)

Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohort
por: Fisher, Anat, et al.
Publicado: (2014)

Therapeutic Drug Monitoring of Certolizumab Pegol: Can Real-World Data Translate to Clinical Practice?
por: Battat, Robert
Publicado: (2021)

Sex Differences in the Association of Sibship Size and Position in Sibship with Lipid Profile during Adolescence: A Cross-Sectional Study
por: Ziyab, Ali H., et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Infliximab in Acute Severe Ulcerative Colitis
por: Gordon, Benjamin L., et al.
Publicado: (2023)

Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
por: Shehab, Mohammad, et al.
Publicado: (2021)

The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study
por: Wu, Chun-Ying, et al.
Publicado: (2014)

Severe erythema multiforme-type drug eruption controlled by tumor necrosis factor-α antagonist: A case study
por: Ling, Xin, et al.
Publicado: (2017)

Impact of treatment with immunomodulators and tumour necrosis factor antagonists on the incidence of infectious events in patients with inflammatory bowel disease
por: Andersson, Per, et al.
Publicado: (2022)

Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases
por: Singh, Siddharth, et al.
Publicado: (2022)

Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review
por: Wang, Liang-Fang, et al.
Publicado: (2023)

Erratum to: The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study
por: Wu, Chun-Ying, et al.
Publicado: (2016)

An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease
por: Patel, Rajan N., et al.
Publicado: (2020)

Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
por: Na, Soo-Young, et al.
Publicado: (2022)

Beta adrenergic antagonists and antianginal drugs
por: Stever, Lindsey M., et al.
Publicado: (2021)

Effectiveness of inspectors' team in increasing compliance with personal protective equipment use and reducing COVID19 infection spread among healthcare workers
por: Shehab, Mohammad, et al.
Publicado: (2021)

Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted?
por: Van den Berghe, Nathalie, et al.
Publicado: (2019)

Management of inflammatory bowel disease with Clostridium difficile infection
por: D’Aoust, Julie, et al.
Publicado: (2017)

Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice
por: Vande Casteele, Niels, et al.
Publicado: (2020)

Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature
por: Kothari, Mansi M, et al.
Publicado: (2017)

The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Fousekis, Fotios S., et al.
Publicado: (2022)

A Saudi Gastroenterology Association Position Statement on the Use of Tumor Necrosis Factor-alfa Antagonists for the Treatment of Inflammatory Bowel Disease
por: Mosli, Mahmoud H., et al.
Publicado: (2015)

1728. A Retrospective Analysis of 49 Cases of Histoplasmosis in Inflammatory Bowel Disease Patients on Tumor Necrosis Factor-α Antagonists
por: Harris, Courtney, et al.
Publicado: (2019)

High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists
por: Guo, Angela, et al.
Publicado: (2022)

Prevalence, Risk Factors, and Fetomaternal Outcomes of Gestational Diabetes Mellitus in Kuwait: A Cross-Sectional Study
por: Groof, Zainab, et al.
Publicado: (2019)

Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations
por: Yang, Derek Z., et al.
Publicado: (2021)

The evaluation of beta blocker and calcium antagonist drugs
Publicado: (1982)

Cannot write session to /tmp/vufind_sessions/sess_arq86f6p1ckm004t71fh66hm33